Physician profile
Lila Cherry
NPI 1922065085
$3,049.23
in general payments reported to CMS, 2019-2025
26 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $961 · 2021: $708 · 2022: $315 · 2023: $257 · 2024: $295 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $514.50 | 2021-2024 | Qulipta, Ubrelvy, Botox |
| Supernus Pharmaceuticals, INC. | $273.74 | 2019-2020 | |
| Sk Life Science, INC. | $246.99 | 2020-2023 | |
| Jazz Pharmaceuticals INC. | $213.90 | 2022-2025 | Epidiolex |
| Greenwich Biosciences, INC. | $205.97 | 2019-2021 | |
| Lilly USA, LLC | $172.05 | 2020-2021 | |
| Amgen INC. | $171.73 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $164.19 | 2020-2022 | |
| Ucb, INC. | $147.12 | 2019-2025 | Fintepla |
| Amneal Pharmaceuticals LLC | $114.16 | 2019-2021 | |
| Kyowa Kirin, INC. | $113.65 | 2020-2021 | |
| Aquestive Therapeutics, INC. | $97.81 | 2020-2021 | |
| Eisai INC. | $94.04 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $92.31 | 2023-2025 | |
| Boston Scientific Corporation | $78.68 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $77.84 | 2019-2022 | |
| Csl Behring | $56.69 | 2019-2021 | |
| Medtronic USA, INC. | $39.16 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $36.90 | 2023 | Rexulti |
| Acorda Therapeutics, INC | $34.06 | 2019 | |
| Neurelis, INC. | $33.78 | 2020 | |
| Biogen, INC. | $17.37 | 2022 | |
| Argenx US, INC. | $16.06 | 2023 | Vyvgart |
| Biohaven Pharmaceuticals, INC. | $13.10 | 2020 | |
| Lundbeck LLC | $11.75 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lila Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.